We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Signal Disruption Causes Some Ovarian Cancers

By Biotechdaily staff writers
Posted on 21 Apr 2005
A recent study has revealed that ovarian cancer in women bearing a mutated form of the BRCA1 gene is caused by disruption of biochemical signaling that also disrupts granulosa cell regulation of epithelial cell growth.

BRCA1, known as the breast cancer gene, not only gives carriers of its mutated form an 80% chance of developing breast cancer, it also confers a 40% percent risk of developing ovarian cancer by the age of 70.

Investigators at the University of Southern California (USA) developed a line of mice lacking the BRCA1gene only in their ovarian granulosa cells. These mice were found to be prone to development of ovarian tumors. However, the tumors did not arise in granulosa tissue. Rather, the tumors originated in epithelial tissue, and they carried normal BRCA1 genes. These findings were published in the March 29, 2005, issue of Current Biology.

"Before, we thought this gene was a classical tumor suppressor,” said senior author Dr. Louis Dubeau, professor of pathology at the University of Southern California. "If that were the case, it would mean that mutation of the gene would allow the cell it is in to grow out of control and create a tumor. Instead, what we have shown is that the gene actually acts indirectly, that it disrupts interactions between different cell types. The consequence of this finding is that ovarian cancer is the result of some biochemical problem that may be correctable or preventable. That is what makes this finding so exciting.”



Related Links:
University of Southern California

Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
New
Rapid Sepsis Test
SeptiCyte RAPID
New
Clinical Informatics Platform
CLARION™

Latest BioResearch News

Study Identifies Protein Changes Driving Immunotherapy Resistance in Multiple Myeloma
21 Apr 2005  |   BioResearch

Genetic Analysis Identifies BRCA-Linked Risks Across Multiple Cancers
21 Apr 2005  |   BioResearch

Study Identifies Hidden B-Cell Mutations in Autoimmune Disease
21 Apr 2005  |   BioResearch